OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)
South Korea
· Delayed Price · Currency is KRW 9,390.00
-210.00 (-2.19%)
At close: Apr 28, 2026
OPTUS Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 87,161 | 81,905 | 72,426 | 58,658 | 57,316 | Upgrade
|
| Other Revenue | - | -0 | -0 | - | - | Upgrade
|
| Revenue | 87,161 | 81,905 | 72,426 | 58,658 | 57,316 | Upgrade
|
| Revenue Growth (YoY) | 6.42% | 13.09% | 23.47% | 2.34% | -5.77% | Upgrade
|
| Cost of Revenue | 39,037 | 37,277 | 31,072 | 27,041 | 24,821 | Upgrade
|
| Gross Profit | 48,125 | 44,628 | 41,354 | 31,617 | 32,495 | Upgrade
|
| Selling, General & Admin | 35,846 | 32,846 | 30,623 | 24,138 | 20,589 | Upgrade
|
| Research & Development | 1,731 | 1,883 | 1,384 | 1,343 | 1,110 | Upgrade
|
| Other Operating Expenses | 234.12 | 260.69 | 164.19 | 184.49 | 110.92 | Upgrade
|
| Operating Expenses | 39,249 | 36,119 | 33,168 | 26,368 | 22,023 | Upgrade
|
| Operating Income | 8,875 | 8,509 | 8,187 | 5,249 | 10,472 | Upgrade
|
| Interest Expense | -69.34 | -97.24 | -124.4 | -85.89 | -8.88 | Upgrade
|
| Interest & Investment Income | 1,328 | 2,373 | 2,296 | 1,401 | 846.43 | Upgrade
|
| Currency Exchange Gain (Loss) | 216.69 | 84.8 | 3.33 | 12.17 | 127.54 | Upgrade
|
| Other Non Operating Income (Expenses) | 281.91 | -469.62 | 11.79 | 21.69 | -36.76 | Upgrade
|
| EBT Excluding Unusual Items | 10,633 | 10,400 | 10,374 | 6,598 | 11,400 | Upgrade
|
| Gain (Loss) on Sale of Investments | 16.32 | 1,242 | 1,967 | 73.39 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 1,939 | 441.87 | 629.3 | 878.29 | 44.24 | Upgrade
|
| Asset Writedown | -1,536 | - | - | -721.2 | -964.98 | Upgrade
|
| Pretax Income | 11,052 | 12,084 | 12,970 | 6,828 | 10,479 | Upgrade
|
| Income Tax Expense | -305.86 | 1,776 | 2,210 | 1,816 | 587.88 | Upgrade
|
| Net Income | 11,358 | 10,308 | 10,760 | 5,012 | 9,892 | Upgrade
|
| Net Income to Common | 11,358 | 10,308 | 10,760 | 5,012 | 9,892 | Upgrade
|
| Net Income Growth | 10.18% | -4.20% | 114.69% | -49.33% | -31.33% | Upgrade
|
| Shares Outstanding (Basic) | 16 | 15 | 15 | 16 | 16 | Upgrade
|
| Shares Outstanding (Diluted) | 16 | 15 | 15 | 16 | 16 | Upgrade
|
| Shares Change (YoY) | 1.88% | 0.53% | -4.22% | -1.07% | -0.62% | Upgrade
|
| EPS (Basic) | 731.00 | 675.00 | 708.35 | 316.00 | 617.00 | Upgrade
|
| EPS (Diluted) | 730.00 | 675.00 | 708.35 | 316.00 | 617.00 | Upgrade
|
| EPS Growth | 8.15% | -4.71% | 124.16% | -48.78% | -30.91% | Upgrade
|
| Free Cash Flow | -28,290 | -2,903 | 9,109 | -3,955 | -3,557 | Upgrade
|
| Free Cash Flow Per Share | -1818.26 | -190.11 | 599.63 | -249.37 | -221.87 | Upgrade
|
| Gross Margin | 55.21% | 54.49% | 57.10% | 53.90% | 56.69% | Upgrade
|
| Operating Margin | 10.18% | 10.39% | 11.30% | 8.95% | 18.27% | Upgrade
|
| Profit Margin | 13.03% | 12.59% | 14.86% | 8.54% | 17.26% | Upgrade
|
| Free Cash Flow Margin | -32.46% | -3.55% | 12.58% | -6.74% | -6.21% | Upgrade
|
| EBITDA | 13,583 | 12,486 | 12,424 | 8,712 | 12,895 | Upgrade
|
| EBITDA Margin | 15.58% | 15.24% | 17.15% | 14.85% | 22.50% | Upgrade
|
| D&A For EBITDA | 4,708 | 3,977 | 4,238 | 3,463 | 2,423 | Upgrade
|
| EBIT | 8,875 | 8,509 | 8,187 | 5,249 | 10,472 | Upgrade
|
| EBIT Margin | 10.18% | 10.39% | 11.30% | 8.95% | 18.27% | Upgrade
|
| Effective Tax Rate | - | 14.69% | 17.04% | 26.60% | 5.61% | Upgrade
|
| Advertising Expenses | 1,033 | 2,032 | 1,515 | 364.81 | 100.36 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.